Patent details

LUC00190 Product Name: Andexanet Alfa

Basic Information

Publication number:
LUC00190
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP161675343
Legal Status:
Inactive
Application number:
LUC00190
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/18/1345
Marketing Authorization Type:
Marketing Authorization Date:
30/04/2019
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
15/12/2020
First Marketing Authorization date:
30/04/2019
Grant date:
14/12/2021
Activation date:
Publication date:
15/12/2020
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
26/09/2033
SPC Extension Expiration:
26/09/2033
Rejection date:
Withdrawal date:

Owner

From:
15/12/2020
 
 

Name:
Alexion Pharmaceuticals, Inc.
Address:
121 Seaport Boulevard, Boston, MA 02210, United States (US)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
15/12/2020
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2021/01
Publication date:
05/01/2021
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
SPC2
Bulletin edition number:
2022/01
Publication date:
03/01/2022
Description:
Section D : Granted supplementary protection certificates – I2 publication

Annual Fees

Annual Fee Due Date:
02/10/2028
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
15/12/2020 Summary of the product caracteristics 35
15/12/2020 General Document 2
15/12/2020 Application Form 4
15/12/2020 MA publication 15
15/12/2020 Outgoing Correspondence 1
15/12/2020 Marketing authorization 3
15/12/2020 Publication 1
14/12/2021 Publication 1
14/12/2021 Certificate 1
14/12/2021 Outgoing Correspondence 1